Jagsonpal Pharma's ₹61 cr cash bet: smart or stretched?

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) spent about ₹61 crore in one quarter on a buyback and an acquisition. It still closed June 2026 with ₹170 crore in cash. What happened Q1 FY27 revenue rose 8.8% to ₹82.2 crore. EBITDA grew 21.4% to ₹19.1 crore, with margin at 23.2% versus 20.8%. Net profit rose 22% to ₹13.2 crore. The company bought back 16 lakh shares at ₹250, a 40% premium, for ₹40 crore. The offer was subscribed 3.67 times. It also paid ₹20.8 crore for 85% of Aequitas Healthcare, a hospital supplies firm with ₹53 crore revenue in FY26. Why it matters Profit is growing 2.5 times faster than sales, thanks to better field force productivity. The buyback lifted ROCE by 340 bps and promoter holding to about 68.9%. My view Bet one is safe. At ₹250, the company paid close to 40 times FY26 earnings. That helps return ratios more than EPS. Nearly half the payout was earned back within the quarter, so the balance sheet barely felt it. Bet two is the real test. Aequitas made only ₹50 lakh EBITDA in FY26. Management targets ₹10 crore by year two. At ₹10 crore, a ₹25 crore deal value is a steal. At ₹50 lakh, it is 50 times. Hospital supplies also carry thinner margins and longer cash cycles, which can dilute a 65% gross margin business. One more flag. Reported growth of 9% trails the 18.9% seen in market data. That gap has to close. What I am watching Q2 FY27 results, due by November: Aequitas margins and whether reported sales catch up. On the chart, ₹250, the buyback price, is the level to reclaim. My stance: Positive on capital discipline, neutral on valuation at about 33 times trailing earnings. Watchlist, not a chase. Disclosure: I do not hold a position in Jagsonpal Pharmaceuticals Limited at the time of writing. This is not investment advice.